Clinical Trials Browser

Neoplasms by Site × HuMax-IL8 × 1 year × Clear all

NCT04572451 2025-08-01

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Phase 1 Recruiting

Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site